Evidence map›Paper›PMID 33526873›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021

Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group.

Olga K Weinberg, Karen M Chisholm, Chi Young Ok, Yuri Fedoriw, Bartosz Grzywacz, Jason H Kurzer, Emily F Mason, Karen A Moser, Siddharth Bhattacharya, Mina Xu and 10 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Updates on Non-B-Lymphoid Neoplasms: A Review of the 5Journal of clinical practice and research · 2024
    Review
  4. Review
  5. Article
  6. EJHaem · 2023
    Article
  7. Review
  8. Review
  9. Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge.Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 1 country.

Olga K WeinbergDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Olga.weinberg@UTSouthwestern.edu.
Karen M ChisholmDepartment of Pathology, Seattle Children's Hospital, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-1898-1252
Chi Young OkDepartments of Hematopathology, M.D. Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6822-7880
Yuri FedoriwDepartment of Pathology, University of North Carolina, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-2135-2908
Bartosz GrzywaczDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Jason H KurzerDepartment of Pathology, Stanford University Medical Center, Palo Alto, CA, USA.
Emily F MasonDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Karen A MoserDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-2258-4444
Siddharth BhattacharyaDepartment of Pathology and Laboratory Medicine, the University of Pennsylvania, Philadelphia, PA, USA.
Mina XuDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA.
Daniel BabuDepartment of Pathology, University of New Mexico, Albuquerque, NM, USA.
Kathryn FoucarDepartment of Pathology, University of New Mexico, Albuquerque, NM, USA.
Wayne TamDepartment of Pathology, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0003-4283-0005
Adam BaggDepartment of Pathology and Laboratory Medicine, the University of Pennsylvania, Philadelphia, PA, USA.
Attilio OraziDepartments of Pathology, Texas Tech University Health Sciences Center, PL Foster School of Medicine, El Paso, TX, USA.
Tracy I GeorgeDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0001-5478-7847
Wei WangDepartments of Hematopathology, M.D. Anderson Cancer Center, Houston, TX, USA.
Sa A WangDepartments of Hematopathology, M.D. Anderson Cancer Center, Houston, TX, USA.
Daniel A ArberDepartment of Pathology and Laboratory Medicine, University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-2160-9689
Robert P HasserjianDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
The University of Texas MD Anderson Cancer Center · USUniversity of New Mexico · USUniversity of Pennsylvania · USUniversity of Utah · USCornell University · USMassachusetts General Hospital · USSeattle Children's Hospital · USSouthwestern Medical Center · USStanford Medicine · USTexas Tech University · USUniversity of Chicago · USUniversity of Minnesota · USUniversity of North Carolina at Chapel Hill · USVanderbilt University Medical Center · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells are lymphocytes of the native immune system that play a pivotal role in host defense and immune surveillance. While the conceptual view of NK-neoplasms is evolving, little is known about the rare NK lymphoblastic leukemia (NK-LL), which remains as a provisional entity in the 2016 WHO Classification. The goal of this study is to characterize NK-LL cases and compare with other CD56 co-expressing acute leukemias. We identified 105 cases, diagnosed as NK-LL (6), CD56+ acute undifferentiated leukemia (AUL) (6), CD56+ T-lymphoblastic leukemia (T-LL) (51), and CD56+ acute myeloid leukemia (AML) (42). Compared to AUL patients, NK-LL patients were significantly younger (p = 0.021) and presented with higher white blood cell (WBC) (p = 0.037) and platelet counts (p = 0.041). Flow cytometry showed more frequent expression of cytoplasmic CD3 (cCD3, p = 0.064) and CD33, (p = 0.065), while HLA-DR was significantly absent from NK-LL (p = 0.035) compared to AUL. Compared to T-ALL, NK-LL cases showed less frequent cCD3 (p = 0.002), CD4 (p = 0.051), and CD10 expression (p = 0.06). The frequency of abnormal karyotypes was similar between NK-LL, AUL, and T-ALL. The mutational profile differed in four leukemia groups, with a significance enrichment of NOTCH1 (p = 0.002), ETV6 (p = 0.002) and JAK3 (p = 0.02) mutations in NK-LL as compared to AML. As compared to T-ALL, NK-LL cases showed a higher number of total mutations (p = 0.04) and significantly more frequent ETV6 mutations (p = 0.004). Clinical outcome data showed differences in overall survival between all four groups (p = 0.0175), but no difference in event free survival (p = 0.246). In this largest study to date, we find that that NK-LL shows clinical presentation, immunophenotypic and molecular characteristics distinct from AUL, T-ALL, and AML. Our findings suggest NK-LL is a distinct acute leukemia entity and should be considered in the clinical diagnosis of acute leukemias of ambiguous lineage.

Indexed as

AdolescentAgedCD56 AntigenChildChild, PreschoolFemaleHumansImmunophenotypingKiller Cells, NaturalMalePrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesCD56 AntigenNCAM1 protein, human

Identifiers

PMID33526873
OpenAlexW3126343938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.